22nd May 2024 12:24
(Alliance News) - Aptamer Group PLC shares rose on Wednesday, after it said it has signed a GBP465,000 agreement with Timser Group.
Shares in the York, England-based biotechnology firm were up 13% to 0.76 pence each in London on Wednesday afternoon.
Timser is a pharmaceutical company focused on women's health.
Aptamer will develop optimer binders to Timser's patented cervical cancer biomarker panel - a three-protein signature that can be used to detect cervical cancer and precancerous lesions. The Optimers will power the world's first blood test for cervical cancer, preventing "invasive smear tests and delivering earlier, more sensitive diagnostics."
Chief Technical Officer Arron Tolley said: "We are delighted to partner with Timser Group to facilitate their ground-breaking cancer diagnostic with Optimer binders. This deal demonstrates the increasing recognition of the Optimer platform to deliver high quality affinity ligands. We believe that implementing Optimer technology will allow our partners to overcome previous issues experienced with antibody variability and supply chains, and we look forward to delivering much-needed improvements to cervical cancer tests."
By Sophie Rose, Alliance News senior reporter
Comments and questions to [email protected]
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Related Shares:
Aptamer Group